Photo by Smith Collection/Gado/Getty Images Getty Images Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD drug manufacturer Verona Pharma for $10 billion, adding yet another potential blockbuster to its expanding collection of post-Keytruda assets. The Verona Deal: What Merck Gets The acquisition of Verona Pharma is a step forward, yet it also underscores the ...